Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | BBNX | LMRI |
|---|---|---|
| Price | $18.08 | $10.59 |
| Change today | ▼ 2.95% | ▼ 1.12% |
| Market cap | $813.41M | $1.02B |
| Return, 3 months | +10.0% | -13.1% |
| Return, year to date | -40.7% | -42.8% |
| Return, 1 year | -18.3% | – |
| P/E (TTM) | -11.1 | -36.6 |
| P/B | 3.2 | 1.7 |
| P/E percentile vs own 5y | 43rd | 23rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +37.8% | +5.1% |
| Net profit growth (YoY) | -38.7% | +138.0% |
| Gross margin | 58.3% | 14.9% |
| Operating margin | -69.8% | 1.4% |
| Net margin | -61.3% | -2.7% |
| Return on equity | -26.2% | -4.5% |
| Analyst target vs. price | +34.8% | +62.1% |
| Analyst buy share | 77% | 100% |
| RSI (14) | 41 | 46 |
| 30-day volatility | 76.9% | 37.1% |
| Max drawdown, 1 year | -72.3% | -63.5% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
